Distant leader in the treatment of cardiovascular disease among all drug manufacturers present on the Bulgarian market with market share 10.57% in 2017 and 11.39% for the first half of 2018 (Source: IQVIA/IMS Health), with deep potential for further growth following the market entry of newly developed and introduced medicaments.